Drug Trial Radar · NCT05998759
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
296
Planned (sponsor's estimate)
Start
Dec 2, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Beijing HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial); Peking University People's Hospital; Peking University Third Hospital; First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; The First Affiliated Hospital of Zhengzhou University; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Second Xiangya Hospital of Central South University; Xiangya Hospital of Central South University; The Affiliated Hospital of Inner Mongolia Medical University; First Hospital of China Medical University; Shandong Provincial Hospital; Changhai Hospital; RenJi Hospital; Shanxi Bethune Hospital; West China Hospital; Institute of Hematology & Blood Diseases Hospital, China; Tianjin First Central Hospital; Tianjin Medical University General Hospital; People's Hospital of Xinjiang Uygur Autonomous Region; The First People's Hospital of Yunnan
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.
Conditions
- Connective Tissue Diseases
- Thrombocytopenia
Interventions
TelitaciceptBiological
subcutaneous telitacicept 160 mg weekly for 24 weeks.
PlaceboDrug
subcutaneous placebo weekly for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response (CR + PR) rateTime frame: at week 24
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical College
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Hefei, Anhui, China · Recruiting
Beijing Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Wuhan Union Hospital, China
Wuhan, Hubei, China · Recruiting
Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China · Recruiting
First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shandong Provincial Hospital
Jinan, Shandong, China · Recruiting
Changhai Hospital
Shanghai, Shanghai Municipality, China · Recruiting
RenJi Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
West China Hospital
Chengdu, Sichuan, China · Recruiting
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China · Recruiting
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting
The First People's Hospital of Yunnan
Kunming, Yunnan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.